Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Business Plan Article
This is a selection made from among articles on Drug Treatment Business Plan. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug Addiction Story
from:Elizabeth was just 13 years old when she had her first drink – this is a story of her descent into drug addiction. After that first drink, she found she liked the way it made her feel, so she had a couple of more. Before long, she experienced her first time being drunk, and the door had opened.
This story of drug addiction usually paints a very similar picture from addict to addict. They share many aspects of their stories and they often share tragic endings.
Elizabeth soon progressed to smoking pot after school, and before long she was using it every day often smoking before school as well. She found it difficult to find enough money to buy her marijuana, so she began taking money from her mother’s purse when she wasn’t looking. It made her feel horrible, so she smoked the pot to help her cope with her guilt.
Drug addiction is no laughing matter. This isn’t a comedy; it’s more of a dramatic story about losing control once and not being able to regain it back.
When Elizabeth was 17, a friend offered her some methamphetamine. By this time, she was known as a party girl and wasn’t about to tarnish that image. She snorted the white powder and was transformed. She became more than the life of the party; she became THE party. People wanted to be around her because she was so much fun. She couldn’t believe it took her so long to find this amazing high.
Have you ever had someone tell you a story you just couldn’t believe? Well when you hear a story about drug addiction, it’s all too true and all too believable. It happens every day.
At 19, Elizabeth had a baby. She wasn’t sure who the father was, and the baby was born addicted to crack. The doctors knew this and her son was taken from her before she was even released from the hospital. Despondent over this loss, when she did leave, she immediately sought out her dealer and got high.
The story of drug addiction is painful to read and painful to tell. For those people who are affected by drug addiction, it’s almost excruciating.
Twenty-one year old Elizabeth was arrested for possession of drugs for the third time in one month. She is put in jail to await trial. The judge orders her into a rehabilitation facility. She attends for the required treatment time and, once home, uses drugs after just two days. At 22, her parents are planning her funeral. She was found in her basement dead from a drug overdose.
The story of drug addiction is often bleak and depressing. The tale is told over and over again all over the world. It’s sad because it’s preventable. Don’t let you or a loved one be another tragic story of drug addiction.
Drug Treatment Business Plan Specific links
Drug Treatment Business Plan News
Horror of heroin descends on Clark County - The Columbian
Horror of heroin descends on Clark County The Columbian Adam Hurd struggled with a two-year heroin addiction before dying of a drug overdose on Aug. 24, 2011. By Laura McVicker Terry Hurd, the father of 24-year-old Adam Hurd, who died last summer of a heroin overdose, remembers his son on May 15, ... |
Green Power Sources & Baby Products are Winners at UCD - Patch.com
Green Power Sources & Baby Products are Winners at UCD Patch.com "The biggest bang in this year's UC Davis business plan competition came from the S2E Energy founder who touted a thin, clear windowlike material said to conduct the sun's power more cheaply and efficiently than existing solar technology. |
Green power sources and baby products win at Big Bang! business competition - UC Davis
 UC Davis | Green power sources and baby products win at Big Bang! business competition UC Davis BOTTOM: Erica Harris (far left) won second place for her Happy Baby Vending plan, and (from second from left clockwise) Jennifer Maguire, Andrew Davidson and Ryan Lore's Roadwise Tech business plan won third place and The People's Choice. |
Business Briefs for May 27, 2012 - The Advocate
Business Briefs for May 27, 2012 The Advocate Baton Rouge biotechnology firm Esperance Pharmaceuticals said it is starting a Phase 2 trial of a drug designed to attack cancer by targeting a potential treatment for advanced ovarian cancer. The molecular structure of Esperance's drug, called EP-100, ... |
REG-Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for ... - Reuters
REG-Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for ... Reuters Summit Corporation plc ('Summit' or 'the Company') Summit Announces Initiation of Phase 1 Trial for the Treatment of Duchenne Muscular Dystrophy Oxford, UK, May 25 th , 2012, Summit (AIM: SUMM), a UK drug discovery company, today announced that it has ... Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for the ... |
Planners to review methadone clinic proposal - Foster's Daily Democrat
Planners to review methadone clinic proposal Foster's Daily Democrat The clinic is scheduled to be reviewed by the site plan review committee Wednesday morning and by the Sanford Planning Board that evening. Methadone is a synthetic narcotic that is used to treat addictions to heroin and other opioid drugs often used in ... |
Gaithersburg drug-maker signs deal for European market - Gazette.Net: Maryland Community News Online
Gaithersburg drug-maker signs deal for European market Gazette.Net: Maryland Community News Online The drug is being studied as an antidote for overexposure to the chemotherapy drug 5-fluorouracil due to dosing errors or from impaired clearance of it from the body, according to a Wellstat statement. 5-fluorouracil has been used for decades to treat ... |
Ed Nemeth - Lodi News-Sentinel
Ed Nemeth Lodi News-Sentinel Employment: He owns a business were he works with pharmaceutical groups when they are developing a new drug to create training programs to educate doctors on the new technology. Education: He graduated with an honors bachelor's degree in neurobiology ... |
FDA panel mixed on Pfizer's rare disease drug - FierceBiotech
FDA panel mixed on Pfizer's rare disease drug FierceBiotech Pfizer's pioneering rare-disease drug tafamidis garnered mixed reviews from FDA advisers Thursday, casting further uncertainty over whether the agency will green-light the treatment for the US market. Both the agency's advisers and staff have harped on ... |
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... - MarketWatch (press release)
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... MarketWatch (press release) CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the ... |